John Strickler, MD, Duke Cancer Center, Durham, NC, describes approaches to mitigate resistance to targeted therapies in colorectal cancer. Enhancing patient selection is critical to increase efficacy of targeted therapy, as only patients who are more likely to benefit will receive the appropriate treatment, creating deeper and more robust responses. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.